The chemokine CXCL10 is crucial for the control of viral replication through the regulation of mobilization of antigen-specific T cells to sites of infection. CXCL10 is highly expressed both at sites of inflammation as well as constitutively within lymphoid organs by both bone marrow (BM)-derived and non-BM-derived cells. However, the relative immunologic importance of CXCL10 expressed by these divergent sources relative to HSV-1 infection is unknown. Using mouse chimeras reconstituted with either wild type or CXCL10 deficient mouse BM, we show BM-derived, radiation-sensitive cells from wild type mice were solely responsible for resistance to HSV-1 in the trigeminal ganglia and brain stem. The resistance was not reflected by a deficiency in the recruitment of effector cells to sites of inflammation or expression of chemokines or IFN-gamma and likely results from additional, yet-to-be-determined factors emanating from wild type, BM-derived cells.
Introduction
Chemokines are a family of small, structurally related proteins which play a central role in the regulation of leukocyte homing. They can be viewed broadly in terms of being either constitutively expressed or inflammatory chemokines. During steady state conditions constitutively expressed chemokines such as the CCR7 ligands CCL19 and CCL21 or the CXCR5 ligand CXCL13, direct the migration of leukocyte subsets to specific spatial compartments within lymphoid organs (Förster, et al., 1999; Stein et al., 2000; Ansel et al., 2002) . As a consequence appropriate positioning of individual cell populations for rapid yet controlled immune responses is maintained (Rossi and Zlotnik, 2000; Zlotnik and Yoshie, 2000) . In contrast, inflammatory chemokines must regulate the rapid initiation of immune responses at sites of inflammation by cocoordinating the selective recruitment of appropriate leukocytes (Rossi and Zlotnik, 2000) . This requires selective up-regulation of chemokine expression at inflammatory sites as well as binding of the chemokine to the extracellular matrix via heparin binding motif/GAG interactions. The localized expression of inflammatory chemokine and chemokine/GAG binding establish a concentration gradient that directs leukocytes towards the chemokine source (Rossi and Zlotnik, 2000; Wuest and Carr, 2008a) .
Recent studies have cast doubts as to whether the primary role of inflammatory chemokines is to simply recruit leukocytes towards inflammatory sites where their expression is up-regulated. For example, findings suggest the primary role of the inflammatory chemokine CCL7 towards monocyte mobilization is to drive monocyte egress out of the bone marrow (Tsou et al., 2007) . Thus, CCL7 expression at inflammatory sites appears secondary to the CCL7/ CCR2-dependent mobilization of monocytes from the bone marrow to the blood stream. In another study, CXCL8 mutants with reduced affinity for extracellular matrix affinity exhibit increased neutrophil chemoattractive properties despite unaltered chemokine receptor affinity (Tanino et al., 2010) . This paradox of increased activity despite presumably attenuated ability to establish local concentration gradients correlated with increased serum concentrations of increasingly active CXCL8 mutants suggesting the possibility of a role for CXCL8 in mobilization of PMNs at sites distant from inflammatory loci. However, leukocytes are not simply the recipients of chemokine cues. Rather, many chemokines are highly expressed by cells of the immune system, and leukocyte-derived chemokine expression is a crucial mechanism by which inflammatory first responders, such as PMNs, drive the influx of adaptive effector cells towards inflammatory loci (Tamassia et al., 2007) .
Viral and bacterial infections elicit distinct and differing chemoinflammatory signals. The chemokine CXCL10, in particular, plays a major role in the control of viral replication as it is highly up-regulated by type I and II interferon and strongly and specifically promotes the chemotaxis of NK, CD4 + , and CD8 + T cells (Trifilo et al., 2004; Klein et al., 2005; Hsieh et al., 2006) . CXCL10 is expressed by cells of both hematopoietic and non-hematopoietic origin (Yoneyama et al., 2002; Drennan et al., 2009) . Further, CXCL10 is expressed not only at sites of inflammation but also constitutively within lymphoid organs (Drennan et al., 2009 
